ArticleJournal of the National Cancer Institute2026
Plasma insulin-like growth Factor-Binding protein 7 predicts 20-Year Cancer-Specific and overall survival in ARIC.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInsulin-like growth factor-binding protein 7 (IGFBP7) may influence physiology by modulating IGF signaling and/or by IGF-independent mechanisms. Prior studies suggest positive associations of circulating IGFBP7 with cancer incidence and all-cause mortality. We analyzed whether IGFBP7 is associated with cancer incidence, cancer mortality, and all-cause mortality.
methodsWe conducted a prospective cohort analysis of 10,834 participants with no cancer history for cancer analyses, and 11,761 participants for all-cause mortality analyses in the Atherosclerosis Risk in Communities study. Participants aged 46-70 years were followed for >2 decades. Plasma IGFBP7 was measured by SomaScan® 5K assay (relative fluorescence units). Incident cancers were ascertained primarily by state cancer registry linkage and mortality confirmed by death certificates. We estimated the association between quartiles of log2-transformed IGFBP7 and outcomes using Cox proportional hazards regression adjusting for age, sex, race/center, and major risk factors, and predicted 20-year survival across IGFBP7 quartiles.
resultsIGFBP7 was positively associated with cancer mortality (1,420 cancer deaths; Q4 vs. Q1: HR = 1.27, 95% CI 1.08-1.50), especially lung (HR = 1.48, 95% CI 1.07-2.05), but not with cancer incidence (3,347 cases; HR = 1.01, 95% CI 0.91-1.12). IGFBP7 was positively associated with all-cause mortality (6,981 deaths; HR = 1.33, 95% CI 1.23-1.43). The highest IGFBP7 quartile had lowest 20-year predicted cancer-specific survival (unadjusted model only) and survival overall. IGFBP7 was not strongly correlated with IGF-1.
conclusionsHigh circulating IGFBP7 may be a risk factor for cancer mortality, especially lung, and all-cause mortality. Our observations justify confirmatory studies and efforts to understand underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.